A Pilot Study of Docetaxel and Trofosfamide as Second-Line ‘Metronomic’ Chemotherapy in the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)

Publisher： Karger

E-ISSN： 2296-5262|31|4|185-189

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.31, Iss.4, 2008-03, pp. : 185-189

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Prospective Phase I/II Study: Combination Chemotherapy with Docetaxel and Pemetrexed as Second-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-07 ,pp. : 435-443

Karger

Access to resources Recommend Favorite

Long-Term Survival after Second-Line Therapy with Docetaxel and Carboplatin and Monthly Pamidronic Acid in a Woman with Metastatic Non-Small Cell Lung Cancer

By  

Oncology Research and Treatment, Vol. 29, Iss. 5, 2006-05 ,pp. : 206-208

Karger

Access to resources Recommend Favorite

Chemotherapy in Elderly Patients with Advanced Lung Cancer Part II: Treatment of Non-Small Cell Lung Cancer (NSCLC)

By  

Oncology Research and Treatment, Vol. 27, Iss. 6, 2004-12 ,pp. : 583-588

Karger

Access to resources Recommend Favorite

Phase II Study of First-Line Sequential Chemotherapy with Gemcitabine-Carboplatin Followed by Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

By  

Oncology, Vol. 68, Iss. 4-6, 2005-08 ,pp. : 382-390

Karger

Access to resources Recommend Favorite

Real‐world chemotherapy treatment patterns in metastatic non–small cell lung cancer: Are patients undertreated?

By  

CANCER, Vol. 121, Iss. 15, 2015-08 ,pp. : 2562-2569

John Wiley & Sons Inc

Access to resources Recommend Favorite